Follow
In December in the Clinical Pipeline column, I covered the FDA approval of the anti-CD3 teplizumab for a novel use: the prevention of type 1 diabetes for individuals at high risk.
Sanofi has just announced that it will buy the company making the drug, Provention Bio, for $2.9 billion.
https://www.sanofi.com/en/media-room/press-releases/2023/2023-03-13-06-00-00-2625367
